Abdominal Pain
|
0.110 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abdominal Pain
|
0.110 |
Biomarker
|
phenotype |
BEFREE |
None of the patients who remained on CFTR modulators developed an episode of AP or required hospitalization for AP related abdominal pain during follow-up.
|
31611131 |
2019 |
Abnormal enzyme/coenzyme activity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal pancreatic duct morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal renal morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormal thrombosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of circulating enzyme level
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Absence of sensation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Based on our data, we can conclude: 1) HNEC brushing is performed without anaesthesia and is well tolerated in all CF patients (children and adults); 2) HNECs can be preserved for up to 48 hours before culture allowings multicentre studies; 3) HNECs culture can be considered a suitable model to study the molecular effects of new CFTR gene mutations and/or uncertain meaning specific mutations of carriers; 4) an ex vivo model of HNECs may be used to evaluate, before human use, the effect of new drugs on patients' cells bearing specific CFTR mutations; 5) the methodology is adequate for a quantitative measurement, by fluorescence, of the CFTR gating activity of the HNECs from patients with different genotypes identifying: a) CF patients bearing two severe mutations with an activity < 10% (compared to controls - 100%); b) CF patients bearing at least a mild mutation with an activity of 10-20%; c) CF carriers (heterozygous subjects) with an activity between 40-70%.
|
27897275 |
2017 |
Acquired obstructive azoospermia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Different cystic fibrosis transmembrane conductance regulator mutations in Chinese men with congenital bilateral absence of vas deferens and other acquired obstructive azoospermia.
|
23953609 |
2013 |
Acute bronchitis and bronchiolitis
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Acute infectious pneumonia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Acute intermittent porphyria
|
0.020 |
Biomarker
|
disease |
BEFREE |
Results of this year's investigations further elucidated the genetic associations of tropical pancreatitis, a reversible mislocalization of ductal CFTR in AIP, the association of asymptomatic pancreatic hyperenzymemia with pancreatic disorders, limitations of diagnostic tests for EPI, diagnosis of chronic pancreatitis by EUS and endoscopic pancreatic function testing and treatment of pain.
|
21844753 |
2011 |
Acute intermittent porphyria
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
CFTR variants are associated with AIP.Because AIP patients with CFTR variants show slower and reduced steroid treatment responses, different treatments should be considered in AIP patients with CFTR variants.
|
25869325 |
2015 |
Acute interstitial pneumonia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Results of this year's investigations further elucidated the genetic associations of tropical pancreatitis, a reversible mislocalization of ductal CFTR in AIP, the association of asymptomatic pancreatic hyperenzymemia with pancreatic disorders, limitations of diagnostic tests for EPI, diagnosis of chronic pancreatitis by EUS and endoscopic pancreatic function testing and treatment of pain.
|
21844753 |
2011 |
Acute interstitial pneumonia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
CFTR variants are associated with AIP.Because AIP patients with CFTR variants show slower and reduced steroid treatment responses, different treatments should be considered in AIP patients with CFTR variants.
|
25869325 |
2015 |
Acute leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia.
|
31541940 |
2019 |
Acute leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results showed CFTR was highly expressed in Ph+ acute leukemia, which protected and maintained the continuous activation of BCR-ABL and the canonical Wnt/β-catenin signaling pathway by decreasing PP2A phosphatase activity.
|
28445932 |
2017 |
Acute pancreatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
None of the patients who remained on CFTR modulators developed an episode of AP or required hospitalization for AP related abdominal pain during follow-up.
|
31611131 |
2019 |
Acute pancreatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our prospective study adds further information about the frequency of CFTR mutations in patients with a single episode of acute pancreatitis.
|
14576497 |
2003 |
Acute pancreatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CFTR IVS8 Poly-T Variation Affects Severity of Acute Pancreatitis in Women.
|
30132293 |
2019 |
Acute pancreatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cystic fibrosis presenting as acute pancreatitis and obstructive azoospermia in a young adult male with a novel mutation in the CFTR gene.
|
12422349 |
2002 |
Acute pancreatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients sharing the same CFTR genotype may or may not experience AP episodes.
|
27086061 |
2017 |
Acute pancreatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the association of cystic fibrosis transmembrane conductance regulator (CFTR) and serine protease inhibitor Kazal type 1 (SPINK-1) gene mutations and monocyte chemoattractant protein 1 (MCP-1) -2518A/G polymorphism with acute pancreatitis (AP), acute recurrent pancreatitis (ARP), and chronic pancreatitis (CP), and to associate genetic backgrounds with clinical phenotype in these three conditions.
|
19844201 |
2010 |
Acute pancreatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CFTR mutations and SPINK-1 polymorphisms are frequent among HIV-positive patients suffering from acute pancreatitis.
|
15238770 |
2004 |
Acute pancreatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We applied an individualized combination of standardized and new CFTR functional bioassays for a patient referred to the Verona CF Center for evaluation after several episodes of acute pancreatitis.
|
31799301 |
2019 |